Maria Luisa Valle

Dr. Maria Luisa Valle

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
MVMaria Luisa Valle
Maria Luisa Valle
BGBitseat Getaneh
Bitseat Getaneh
CWChristopher M. William
Christopher M. William
JGJorge Ghiso
Jorge Ghiso
ARAgueda A. Rostagno
Agueda A. Rostagno
Cerebral amyloid angiopathy (CAA), present in more than 90% of Alzheimer’s disease (AD) cases, associates with focal ischemia and neurovascular dysfunction. Genetic variants at positions 21–23 of amyloid beta (Aβ), among them the Dutch mutation (AβE22Q), are primarily linked to CAA and the development of cerebral hemorrhages. An important contributor to CAA pathogenesis is the dysregulation of mitochondria-mediated pathways with concomitant induction of oxidative stress. Using biochemical assays and immunofluorescence microscopy, this work demonstrates the exacerbated formation of reactive oxygen species (ROS) in human brain microvascular endothelial cells after short exposure to soluble oligomers of synthetic homologues of Aβ1-42 and the Dutch variant, inducing lipid peroxidation and protein carbonylation, both markers of oxidative stress. The heterogeneity of the soluble oligomeric assemblies inducing this oxidative response was highlighted by their reactivity with two conformational antibodies recognizing specific and mutually exclusive epitopes associated with either soluble prefibrillar oligomers or soluble fibrillar oligomers. Treatment with the multitarget antioxidants Trolox and methazolamide significantly attenuated the Aβ-mediated ROS production and reduced oxidative stress markers to basal levels. Our data highlight the damaging role of heterogeneous Aβ oligomers and the preventing effect of antioxidants, suggesting ROS modulation as a complementary therapeutic strategy to preserve neurovascular unit integrity.

2 June 2025 in STAR Protocols
Verified
Journal Article
Open access
MVMaria Luisa Valle
Maria Luisa Valle
BGBitseat Getaneh
Bitseat Getaneh
JLJames Loveland
James Loveland
HEHediye Erdjument-Bromage
Hediye Erdjument-Bromage
CWChristopher William
Christopher William
JGJorge Ghiso
Jorge Ghiso
Alzheimer's disease (AD) is characterized by the deposition of full-length and truncated amyloid beta (Aβ) species within brain parenchyma and cerebral vessels. However, Aβ truncated species remain understudied. Here, we present a protocol for culture and characterization of a mouse monoclonal antibody targeting N-terminally truncated proteoforms starting at position 4. We describe a detailed procedure for hybridoma culture, antibody collection, and isolation via affinity chromatography. We then describe steps for target validation via dot blot, as well as potential applications. For complete details on the use and execution of this protocol, please refer to Cabrera et al. and Rostagno et al.1,2.


1 March 2026 in Ibrain
Verified
Journal Article
Open access
MVMaria Luisa Valle
Maria Luisa Valle
DADonatello Arienzo
Donatello Arienzo
Alzheimer's disease (AD) pathogenesis is characterized by the accumulation of amyloid beta (Aβ) deposits in the cerebral parenchyma and vasculature, a condition referred to as cerebral amyloid angiopathy (CAA). Besides the full‐length form, Aβ deposits showed a highly heterogenous composition due to the action of different proteolytic enzymes. N‐terminal Aβ peptides have shown higher aggregation propensity and toxicity compared to the other truncated forms, with species starting at residue phenylalanine 4 (Aβ4‐x) being more neurotoxic than the others. Thus, Aβ4‐x species have drawn attention in AD pathogenesis, potentially offering novel therapeutic targets to halt or reverse disease progression. Antibodies targeting specifically Aβ4‐x species were designed with the aim of preventing their aggregation and promoting their clearance counterbalancing their neurotoxic effect. This work provides an update on monoclonal and polyclonal antibodies developed to specifically target Aβ4‐x species in AD and CAA preclinical studies (in vitro and in vivo models).

11 September 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
MVMaria Luisa Valle
Maria Luisa Valle
CJChristopher Lawrence Carlos De Jesus
Christopher Lawrence Carlos De Jesus
BGBitseat Getaneh
Bitseat Getaneh
HEHediye Erdjument-Bromage
Hediye Erdjument-Bromage
JLJames Loveland
James Loveland
JGJorge Ghiso
Jorge Ghiso
Hyperhomocysteinemia (HHcy), a risk factor for cardiovascular, neurodegenerative, and metabolic dysfunctions in humans, has been recapitulated in murine models by genetic and dietary modifications. The relevance of HHcy in clinical and experimental settings has led to the development of various analytical techniques with varying sensitivity and sample volume requirements. This study uses a fit-for-purpose, small-volume LC-MS/MS workflow to quantify plasma homocysteine (Hcy), methionine (Met), and cysteine (Cys) in a diet-induced HHcy mouse model. Using these assays that overcome limitations imposed by sample availability in small animals, our study evaluated circulating levels of these amino acids in C57BL/6 mice fed a HHcy-inducing diet rich in Met and lacking vitamins B6, B9, and B12. The increased Hcy and decreased Cys plasma concentrations observed in these mice correlated with decreased glutathione concentrations in brain homogenates and concomitant increase in the activity of the antioxidant enzyme Glutathione-S-Transferase and in the levels of the lipid peroxidation marker malondialdehyde. Overall, our work links plasma HHcy to the induction of brain oxidative stress, supporting the role of dietary modifications as complementary therapeutic strategies for neurodegenerative conditions.